A comprehensive review of the 2025 meta-analysis examining low dose naltrexone for fibromyalgia. Does LDN actually work for chronic pain? We break down 8 clinical trials, the TLR-4 mechanism, real effect sizes, and what patients should know before trying this off-label treatment.
A 2023 meta-analysis of 11 RCTs and 774 patients reveals Palmitoylethanolamide (PEA) significantly reduces chronic pain with a large effect size. Is this the science-backed supplement fibromyalgia patients have been waiting for?
Central sensitization is when your nervous system turns up the volume on pain signals—but it's reversible. This science-based guide explains what central sensitization really is, why it happens, and evidence-based treatments that can help rewire your pain system.
In August 2025, the FDA approved Tonmya—the first new fibromyalgia treatment in over 15 years. Combined with established therapies and emerging research, patients now have more evidence-based options than ever.
New research and real-world health tracking data reveal how barometric pressure and weather changes affect chronic pain. Discover the science behind the weather-pain connection and evidence-based strategies for managing symptoms.